Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease

Clinical Respiratory Journal

Volumn 9, Issue 3, 2015, Pages 330-341

  Wang, Huaying ^a   Ying, Huajuan ^a   Wang, Shi ^a   Gu, Xiao ^a   Weng, Yuesong ^b   Peng, Weidong ^a   Xia, Dajing ^c   Yu, Wanjun ^a  

^a NINGBO UNIVERSITY   (China)

^b NINGBO FIRST HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

COPD; Immune imbalance; Pulmonary function; Regulatory T cells; Th17 cells

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL FUMARATE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; MUSCARINIC RECEPTOR BLOCKING AGENT; RETINOID RELATED ORPHAN RECEPTOR GAMMA; SALMETEROL XINAFOATE; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MESSENGER RNA;

ARTICLE; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOPATHOGENESIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SMOKING; TH17 CELL; AGED; CASE CONTROL STUDY; CHINA; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; CASE-CONTROL STUDIES; CHINA; FEMALE; FORCED EXPIRATORY VOLUME; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, MESSENGER; SMOKING; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84936950673     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/crj.12147     Document Type: Article

References (48)

1. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4: 435-459.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3: e442.
3. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc. 2007;4: 522-525.
4. Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007;4(8): 626-634.
5. Domagała-Kulawik J, Hoser G, Dabrowska M, Chazan R. Increased proportion of Fas positive CD8+ cells in peripheral blood of patients with COPD. Respir Med. 2007;101(6): 1338-1343.
6. Gadgil A, Duncan SR. Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3: 531-541.
7. Curtis JL, Freeman CM, Hogg JC. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc. 2007;4: 512-521.
8. Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest. 2008;118: 394-402.
9. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. NIH Publication no. 2701:1-100.
10. Rabe KF, Hurd S, Anzueto A, etal. Bethesda, MD: National Heart, Lung and Blood Institute, April 2001. Last update 2008. Available at: http://www.goldcopd.com (accessed 12 March 2009). 2.
11. Hogg JC, Chu F, Utokaparch S, etal. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350: 2645-2653.
12. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, Mapp CE, Fabbri LM, Donner CF, Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med. 1998;158: 1277-1285.
13. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360: 2445-2454.
14. van der Strate BW, Postma DS, Brandsma CA, Melgert BN, Luinge MA, Geerlings M, Hylkema MN, van den Berg A, Timens W, Kerstjens HA. Cigarette smoke-induced emphysema: a role for the B cell? Am J Respir Crit Care Med. 2006;173: 751-758.
15. Lee SH, Goswami S, Grudo A, etal. Anti-elastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007;13: 567-569.
16. Cosio MG. Autoimmunity, T-cells and STAT-4 in the pathogenesis of chronic obstructive pulmonary disease. Eur Respir J. 2004;24: 3-5.
17. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361: 888-898.
18. Hirota K, Martin B, Veldhoen M. Development, regulation and functional capacities of Th17 cells. Semin Immunopathol. 2010;32: 3-16.
19. Vargas-Rojas MI, Ramírez-Venegas A, Limón-Camacho L, Ochoa L, Hernández-Zenteno R, Sansores RH. Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease. Respir Med. 2011;105: 1648-1654.
20. Di Stefano A, Caramori G, Gnemmi I, etal. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol. 2009;157: 316-324.
21. Doe C, Bafadhel M, Siddiqui S, etal. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest. 2010;138: 1140-1147.
22. Lee YK, Mukasa R, Hatton RD, Weaver CT. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol. 2009;21: 274-280.
23. Domagała-Kulawik J, Hoser G, Dabrowska M, Safianowska A, Chazan R. CD4+/CD25+ cells in systemic inflammation in COPD. Scand J Immunol. 2011;73: 59-65.
24. Wang H, Peng W, Weng Y, Ying H, Li H, Xia D, Yu W. Imbalance of Th17/Treg cells in mice with chronic cigarette smoke exposure. Int Immunopharmacol. 2012;14: 504-512.
25. Miller MR, Hankinson J, Brusasco V, etal. Standardisation of spirometry. Eur Respir J. 2005;26(2): 319-338.
26. Yoshida T, Tuder RM. Pathobiology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev. 2007;87: 1047-1082.
27. Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol. 2008;38: 921-924.
28. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9: 239-244.
29. Isajevs S, Taivans I, Strazda G, Kopeika U, Bukovskis M, Gordjusina V, Kratovska A. Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J. 2009;33: 61-67.
30. Smyth LJ, Starkey C, Vestbo J, Singh D. CD4-regulatory T-cells in COPD patients. Chest. 2007;132: 156-163.
31. Barceló B, Pons J, Ferrer JM, Sauleda J, Fuster A, Agustí AG. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J. 2008;31: 555-562.
32. Hou J, Sun Y, Hao Y, Zhuo J, Liu X, Bai P, Han J, Zheng X, Zeng H. Imbalance between subpopulations of regulatory T cells in COPD. Thorax. 2013;68: 1131-1139.
33. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30: 531-564.
34. Tobacco Smoking. European Lung White Book. The European Respiratory Society, 2004: 108-124.
35. Harrison OJ, Foley J, Bolognese BJ, Long E III, Podolin PL, Walsh PT. Airway infiltration of CD4+ CCR6+ Th17 type cells associated with chronic cigarette smoke induced airspace enlargement. Immunol Lett. 2008;121: 13-21.
36. Shapiro SD, Reilly JJJ, Rennard SI. Chronic bronchitis and emphysema. In: Mason RJ, Martin TR, King TE Jr, Schraufnagel DE, Murray JF, Jay A, editors. Nadel Textbood of Respiratory Medicine, Vol. I. Philadelphia, PA, Saunders, 2010: 919-967.
37. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374: 733-743.
38. Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1 beta. Monaldi Arch Chest Dis. 2010;73: 86-87.
39. Nguyen V, Luzina I, Rus H, Tegla C, Chen C, Rus V. IL-21 promotes lupus-like disease in chronic graft-vs-host disease through both CD4 T cell- and B cell-intrinsic mechanisms. J Immunol. 2012;189: 1081-1093.
40. Nurieva R, Yang XO, Martinez G, etal. Essential auto-crine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448: 480-483.
41. Rico de Souza A, Zago M, Pollock SJ, Sime PJ, Phipps RP, Baglole CJ. Genetic ablation of the aryl hydrocarbon receptor causes cigarette smoke-induced mitochondrial dysfunction and apoptosis. J Biol Chem. 2011;286: 43214-43228.
42. Ramirez JM, Brembilla NC, Sorg O, Chicheportiche R, Matthes T, Dayer JM, Saurat JH, Roosnek E, Chizzolini C. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper cells. Eur J Immunol. 2010;40: 2450-2459.
43. Zhang L, Cheng Z, Liu W, Wu K. Expression of interleukin (IL)-10, IL-17A and IL-22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD. 2013;10: 459-465.
44. Massagué J. TGF-β signalling in context. Mol Cell Biol. 2012;13: 616-630.
45. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9: 641-649.
46. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, Soumelis V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008;9: 650-657.
47. Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc. 2009;6: 532-534.
48. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379: 1341-1351.